256 related articles for article (PubMed ID: 22789974)
1. Glycemic management in diabetes and the associated cardiovascular risk: are we helping or hurting our patients?
Koshizaka M; Green JB; Alexander JH
Circ J; 2012; 76(7):1572-80. PubMed ID: 22789974
[TBL] [Abstract][Full Text] [Related]
2. Glycemic control and cardiovascular mortality.
Riddle MC
Curr Opin Endocrinol Diabetes Obes; 2011 Apr; 18(2):104-9. PubMed ID: 21522000
[TBL] [Abstract][Full Text] [Related]
3. [Cardiovascular outcome trials in patients with diabetes].
Mannucci E
G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):27S-31S. PubMed ID: 25623548
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic Medications.
Alvarez CA; Lingvay I; Vuylsteke V; Koffarnus RL; McGuire DK
Clin Pharmacol Ther; 2015 Aug; 98(2):145-61. PubMed ID: 25963811
[TBL] [Abstract][Full Text] [Related]
5. Diabetes, prediabetes and cardiovascular risk.
Mellbin LG; Anselmino M; Rydén L
Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S9-14. PubMed ID: 20489420
[TBL] [Abstract][Full Text] [Related]
6. Benefits and harms of intensive glycemic control in patients with type 2 diabetes.
Rodriguez-Gutierrez R; Gonzalez-Gonzalez JG; Zuñiga-Hernandez JA; McCoy RG
BMJ; 2019 Nov; 367():l5887. PubMed ID: 31690574
[TBL] [Abstract][Full Text] [Related]
7. Draft FDA guidance for assessing the safety of glucose lowering therapies: a missed opportunity?
Khunti K; Davies MJ; Marx N; Buse JB
Lancet Diabetes Endocrinol; 2020 Oct; 8(10):810-811. PubMed ID: 32946819
[No Abstract] [Full Text] [Related]
8. Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight.
Coch RW; Green JB
Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):767-72. PubMed ID: 27378397
[TBL] [Abstract][Full Text] [Related]
9. Divergent effects of various diabetes drugs on cardiovascular prognosis.
Bell DS; Patil HR; O'Keefe JH
Rev Cardiovasc Med; 2013; 14(2-4):e107-22. PubMed ID: 24448252
[TBL] [Abstract][Full Text] [Related]
10. Strategies for the development of new PPAR agonists in diabetes.
Cavender MA; Nicholls SJ; Lincoff AM
Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S32-7. PubMed ID: 20489419
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
12. Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta-Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials.
Giugliano D; Maiorino MI; Bellastella G; Chiodini P; Esposito K
J Am Heart Assoc; 2019 Jun; 8(12):e012356. PubMed ID: 31166153
[TBL] [Abstract][Full Text] [Related]
13. Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence.
Rodríguez-Gutiérrez R; Montori VM
Circ Cardiovasc Qual Outcomes; 2016 Sep; 9(5):504-12. PubMed ID: 27553599
[TBL] [Abstract][Full Text] [Related]
14. Antihyperglycemic drugs and cardiovascular outcomes in type 2 diabetes.
Ganda OP
Cleve Clin J Med; 2016 May; 83(5 Suppl 1):S11-7. PubMed ID: 27176677
[TBL] [Abstract][Full Text] [Related]
15. [Cardiovascular risk reduction in the management of diabetic patients: what has changed since the '90s in the clinical approach?].
Consoli A; Di Fulvio P
G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):21S-26S. PubMed ID: 25623547
[TBL] [Abstract][Full Text] [Related]
16. Diabetes management: More than just cardiovascular risk?
Zimmerman RS; Pantalone KM
Cleve Clin J Med; 2014 Nov; 81(11):672-6. PubMed ID: 25368217
[No Abstract] [Full Text] [Related]
17. Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy.
Spallarossa P; Barsotti A; Cordera R; Ghigliotti G; Maggi D; Brunelli C
J Endocrinol Invest; 2004 May; 27(5):485-95. PubMed ID: 15279085
[TBL] [Abstract][Full Text] [Related]
18. Hypoglycaemic therapy in type 2 diabetes. Part I. Metformin is the only glucose-lowering drug known to prevent complications of diabetes.
Prescrire Int; 2015 Apr; 24(159):103-6. PubMed ID: 25941708
[TBL] [Abstract][Full Text] [Related]
19. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
Dailey G
Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
[TBL] [Abstract][Full Text] [Related]
20. Diabetes: Prevalence, prognosis and management of a potent cardiovascular risk factor.
Norhammar A; Mellbin L; Cosentino F
Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):52-60. PubMed ID: 28618910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
